AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06665204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care
Description: Standard-of-care physical therapy will be provided by a licensed outpatient staff physical therapist who is not associated with the research team. The outpatient physical therapists will not treat participants in the CPG-adherent group and will be free to treat their participants based on their current personal and organizational clinical practice standards. The research team will neither influence nor restrict the evaluations conducted or interventions provided.
Study NCT06665152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProTaper File System
Description: A rotary file system
Study NCT06665152 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WaveOne File System
Description: A reciprocating file system
Study NCT06601569 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: balance and range of motion
Description: * Spinal alignment and range of motion measure scale (SAROMM): is a measure of spinal alignment and range of motion using standard physical therapy techniques scored on a 5-point ordinal score of 0 (normal alignment and range with active correction) to4 (severe ﬁxed deformity) (Bartlett ey al., 2005)~* Modified Ashworth scale (MAS): is a measure of muscle motion and scoring the perceived resistance to movement on a scale of 1 (no increase in tone) to 5 (rigid in ﬂexion or extension) (Clopton et al., 2005).~* Early clinical assessment of balance (ECAB) scale: Is a 13-item test that estimates postural stability for children with CP across all levels of functional ability (Jeffries etal., 2016).~* Functional strength assessment scale: Therapists completed a functional strength assessment (FSA) to obtain an estimate of strength for major muscle groups including the neck and trunk ﬂexors and extensors, and hip extensors, knee extensors, and shoulder ﬂexors bilaterally.
Study NCT06395506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Those randomized to receive creatine (experimental group) will be initially dosed at 20 g/day for 7 days to boost availability of creatine systemically. Thereafter, the dose will be reduced to 5 g/day for maintenance through the duration of the 12-week protocol.
Study NCT06667752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced Antibacterial Wound Dressing
Description: For the first 4 weeks, wound dressing will be changed twice weekly. Subsequently, dressing selection and change frequency will be managed by the investigator as part of the standard of care for another 8 weeks.
Study NCT06667752 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Ag+ Extra
Description: For the first 4 weeks, wound dressing will be changed twice weekly. Subsequently, dressing selection and change frequency will be managed by the investigator as part of the standard of care for another 8 weeks.
Study NCT06088004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABO2011 Injection
Description: Name of Active Ingredient: mRNA encoding human single-chain IL-12 protein; ABO2011 injection Route of administration: intratumoral injection
Study NCT06088004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Anti-PD-1 antibody
Study NCT06667388 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Group A
Description: each participant of this groups will receive 4 weeks of FWT and 4 weeks of BWT (the training order of A group will FWT and BWT), with a washout period of 2 weeks during the post-intervention phase of the 1st period and the pre-intervention phase for the 2nd period.
Study NCT06667388 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Grojup B
Description: each participant of B group will receive 4 weeks of BWT and 4 weeks of FWT (the training order of group B will be BWT and FWT, opposite to group A), with a washout period of 2 weeks during the post-intervention phase of the 1st period and the pre-intervention phase for the 2nd period.
Study NCT06667531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 3 mm.
Study NCT06667531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 2 mm.
Study NCT06667531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of an immediate intermediate abutment (in implant placement surgery). This abutment has a height of 1.5 mm.
Study NCT06667531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 3 mm.
Study NCT06667531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 2 mm.
Study NCT06667531 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant
Description: Placement of a delayed intermediate abutment (in the second implant surgery). This abutment has a height of 1.5 mm.
Study NCT06667492 — intervention group
Intervention type: DEVICE
Intervention: Traction Dynamometry
Description: K-Pull dynamometer (Model MP.09.02.FN, Kinvent, Montpellier, France) is an assessment tool used to quantify muscle strength. It uses traction through a non-elastic strap to facilitate isometric contractions. This instrument will be used to evaluate isometric activity (maximum and average torque values) of the hip and knee flexors and extensors at specific joint angles.
Study NCT06666348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirdametinib
Description: Participants will receive orally administered mirdametinib in combination with intravenous vinblastine chemotherapy
Study NCT06667024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine
Description: Patients received the standard spinal anesthesia with 0.5% 3 ml according to the patient hyperbaric bupivacaine only
Study NCT06667024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and Hyperbaric bupivacaine
Description: Patients received dexmedetomidine 4 μg and 0.5% (3-4 ml according to the patient height) hyperbaric bupivacaine
Study NCT06094413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent Training Intervention
Description: The intervention was implemented and supervised by a well-trained, highly experienced professional with post-graduate education in the fields of exercise science and health promotion. Each session consisted of three phases: warm-up/initiation, conditioning, and cooldown. The intervention was composed of aerobic, resistance, balance, and flexibility exercises. At each session subjects werre informed of the program goals and the methods used to document exercise tolerance of the session's training loads. The quality of the intervention was measured by patient compliance, adherence, and feedback such as rates of perceived exertion (RPE) which were monitored during the session to measure immediate effect of the intervention. Progressions were guided by individual responsiveness and measured by RPE. Progressions were based on the training principles of specificity, adaptability, and overload.
Study NCT06621745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude Intervention App
Description: The GIA app, an iOS application designed for this study, is based on effective gratitude interventions and tailored for youth. Access required a unique login. It features five exercises: a journal, photo book, imagine exercise, speech exercise, and meditation. The journal encourages daily entries. The photo book involves uploading photos of things users are grateful for, promoting mindfulness. The imagine exercise reflects on gratitude, while the speech exercise records users' gratitude. The meditation exercise enhances well-being. During the three-week study, daily notifications prompted exercise completion. The app, green and white with a flower-heart icon, offers email support for technical issues.
Study NCT06618079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-565-A, HUC2-565-A and HUC2-565-B
Description: Cohort A received HUC2-565-A for 5 days, followed by HUC2-565-A and HUC2-565-B for 9 days.
Study NCT06618079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HUC2-565-B, HUC2-565-A and HUC2-565-B
Description: Cohort B takes HUC2-565-B for 9 days, then HUC2-565-A and HUC2-565-B for 5 days.
Study NCT06620679 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (LPS)
Description: Lipopolysaccharide (LPS), single i.v. bolus, 0.4 ng/kg body weight
Study NCT06620679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal saline, single i.v. bolus, in equal volume to intervention
Study NCT06653556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LCAR-AIO T cells
Description: Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.
Study NCT05752955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMARThealth Pregnancy
Description: At each visit, the CHW will:~* Update history and contact details~* Check haemoglobin with a point of care device.~* Check BP~* Check iron folic acid (IFA) supply and compliance~* Brief screen for mental health problems~An electronic decision support platform will provide advice if referral is needed. At the Primary Health Centre, doctor/s will be issued a tablet computer with a version of the SMARThealth Pregnancy App to:~* Generate an automated list of all patients in the community who require review, with the dates of testing and referral, and with two-way communication back to the CHW.~* Suggest management based on current Indian guidelines for the diagnosis and management of anaemia, hypertension and diabetes in pregnant and non-pregnant adults.
Study NCT06618391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: Envolimab :150 mg/time, intratumoral injection, at least 5 sites; Recombinant human endostatin： Q3W for 4-6 cycles，Maintenance therapy 210 mg ,CIV 72 hours ,administered as continuous intravenous pump, administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
Study NCT06618391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin
Description: Recombinant human endostatin: 15mg/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
Study NCT06618391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human adenovirus type 5
Description: Recombinant Human Adenovirus Type 5: 1.0ml/time, intratumoral injection, at least 5 sites; Envolimab :Maintenance therapy 300 mg, Q3W for 4-6 cycles，, subcutaneous injection; administered on Day 1 of each cycle; Docetaxel: 60-75 mg/m2, D1, Q3W,for 4-6 cycles，intravenous drip.
Study NCT06620536 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: Electrical stimulation of peripheral nerves for the recovery of hand function in tetraplegic patients of fundamental importance in improving quality of life.
Study NCT06683963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebee
Description: Tablet device with accompanying sensor device. Tablet device is preloaded with exercises, to be taught to patients during their hospital stay, and to be continued post-discharge
Study NCT06684951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: observe hCG effect on endometrial receptivity
Study NCT06621160 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: After the participants\&#39; physical and sociodemographic characteristics were recorded, they were asked to fill out the Constipation Severity Scale and 7- Day Stool Diary to determine their constipation levels. The individuals\&#39; anthropometric characteristics were assessed with triceps, subscapula, suprailiac and calf skinfold thickness, humerus and femur epicondyle diameter, biceps and calf circumference measurements, spinal postures were assessed with the Spinal Mouse, and physical activity levels were assessed with the International Physical Activity Questionnaire-Short Form UFAA-KF and pedometer.
Study NCT06502795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protected Range Quadriceps Strengthening group
Description: Warm-up: Start with 5 minutes of stationary biking. Then, proceed with two sets of 30-second dynamic stretches targeting the quadriceps, hamstrings, calf muscles, and adductors, followed by static stretching for the abductors.~Strengthening: Complete 3 sets of 8-12 repetitions for each exercise, aiming for a perceived effort level on the Borg scale between 60% and 80%. Increase the load by 2%-10% when the patient can perform 14 or more repetitions in the final set while maintaining the Borg scale between 60% and 80%.~For the Leg Extension Machine, maintain a range of motion between 90 to 45 degrees. During Squats and Bulgarian Squats, aim for a range of motion between 0 to 45 degrees.
Study NCT06502795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient-Guided Range Quadriceps Strengthening group
Description: Warm-up: 5 minutes of stationary biking. Next, perform two sets of 30-second stretches for the quadriceps, hamstrings, calf muscles, adductors and abductors hip.~Strengthening: Patients will complete 3 sets of 8 to 12 repetitions for each exercise, aiming for a perceived effort level of 60% to 80% on the Borg scale. Load will be increased by 2% to 10% when patients can complete 14 or more repetitions in the final set while maintaining the Borg scale between 60% and 80%.~Quadriceps strengthening will be performed at the patient's maximum range guided by symptoms, with pain intensity capped at 5 points on the NPRS. The patient-guided range will be adjusted based on pain intensity, comfort, and patient response, using a shared decision-making approach. The goal is to maintain exercises at the maximum possible range of motion.~For the Leg Extension Machine, Squats, and Bulgarian Squats, the range of motion will be guided by the patient's pain tolerance.
Study NCT06685458 — intervention group
Intervention type: OTHER
Intervention: Preoperative Clinical and Imaging Feature Evaluation for Predictive Modeling
Description: This study involves preoperative evaluation of clinical and imaging features for constructing a predictive model to differentiate benign and malignant solid pulmonary nodules. Surgical resection is performed to obtain pathological confirmation as the reference standard.
Study NCT06684509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atrovastain
Description: atorvaststin 40mg/daily , started before anthracyclin treatment and continued 12 months
Study NCT06631521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: 600 mg (two 300 mg tablets) taken orally twice daily.
Study NCT06631521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix
Description: A loading dose of 360 mg on the first day, followed by 120 mg taken orally once daily.
Study NCT06631521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Performed at least 48 hours and within 2 weeks after the completion of neoadjuvant therapy.
Study NCT06617819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CR prosthesis
Description: For patients undergoing simultaneous bilateral knee arthroplasty, different prostheses (CR vs. PS) were randomized to the left or right knee.
Study NCT06617819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS prosthesis
Description: For patients undergoing simultaneous bilateral knee arthroplasty, different prostheses (CR vs. PS) were randomized to the left or right knee.
Study NCT06621888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTI164
Description: This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164), specifically formulated to treat pediatric acute-onset neuropsychiatric syndrome (PANS). The dosing regimen is carefully structured to increase from an initial 5 mg/kg per day up to a maximum of 20 mg/kg, tailored to individual tolerance levels. This gradual titration and the option to extend treatment up to 54 weeks distinguishes it from other interventions that may use different concentrations of THC or shorter treatment durations. The efficacy of NTI164 is rigorously assessed through psychological evaluations and biomarker analyses.
Study NCT06685523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subgingival debridement
Description: To be applied 1 times (0. days)
Study NCT06685523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser decontamination
Description: To be applied 3 times
Study NCT06685523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diyot laser decontamination
Description: To be applied 3 times
Study NCT05354102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMC128
Description: A live bio-therapeutic product composed of 4 commensal bacterial strains, natural inhabitants of the human intestinal tract.
Study NCT05354102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A human monoclonal antibody that blocks programmed-death-1 (PD-1). It is a type of immunotherapy and works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer.
Study NCT05667831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alginate silver silver ion dressing
Description: Alginate silver silver ion dressing is a soft, comfortable wound dressing with a high mannuronic acid content. Gels on contact with wound exudate or blood, creating a moist wound environment for optimal wound healing. Silver ions protect the dressing from a range of microorganisms.
Study NCT04977336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.
Study NCT04977336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB/APAP
Description: Capsules for oral administration.
Study NCT04977336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.
Study NCT04977336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to VX-548)
Description: Placebo matched to VX-548 for oral administration.
Study NCT04977336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.
Study NCT04977336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (matched to HB/APAP)
Description: Placebo matched to HB/APAP for oral administration.
Study NCT06206551 — intervention group
Intervention type: OTHER
Intervention: Spiritual Needs Questionnaire
Description: This questionnaire captures the spiritual needs of patients and is used in its short version (screener).This questionnaire is used as part of standard treatment for all palliative care inpatients.
Study NCT04398485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION251
Description: ION251 administered by IV infusion
Study NCT05500248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leave In Situ
Description: Polyps will be left in situ if diminutive (≤5 mm) in size, located in the rectum or sigma and optically diagnosed by the endoscopist using the system to be hyperplastic with high confidence, otherwise resected and sent to pathology.~This behaviour is recommended by guidelines if the endoscopist is expert in optical diagnosis. In this case the endoscopists will be experts and they will also be helped by the CADx system that has shown to exceed the thresholds requested for use in clinical practice in previous trials.
Study NCT05500248 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: All identified polyps will be removed and sent to pathology.
Study NCT05684510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: clear aligners
Description: clear aligners will be applied to the upper and lower arch, then a class II elastics 1\\4 and 6,5 oz will be use from the precision-cut Hook on the maxillary aligner to the button of mandibular first molar
Study NCT05684510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional treatment Fixed appliances with class II elastics.
Description: Agroup of patients in which participants will be undergo to the fixed multibracket treatment (with slot size 0.022 × 0.028 and MBT prescription , after completing leveling and alignment , Elastics will be applied from the hooks of canines brackets to the hooks of lower first molar when the 0.019× 0.025-inch stainless steel archwires placed.
Study NCT05930795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pectopexy
Description: pectopexy: surgery performed by suspending prolapsed uterus or vault to the pectineal ligament
Study NCT05930795 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral suspension
Description: lateral suspension: surgery performed by suspending prolapsed uterus or vault to the lateral walls of the abdomen corresponding to the 3 cm anterior superior to the iliac crest
Study NCT06433622 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Repeat Thromboelastography with Platelet Mapping
Description: Thromboelastography (TEG) is an assay used by many medical professionals to assess coagulopathy, predict outcomes, and guide treatment. Although TEG does not assess platelet function very well, a TEG with platelet mapping (TEG-PM) assay assesses platelet functioning by measuring the percent of arachidonic acid (AA) and adenosine diphosphate (ADP) that are inhibited in the patient's blood.